nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—UGT2B7—renal system—cervical cancer	0.0297	0.0586	CbGeAlD
Naproxen—AKR1C3—uterine cervix—cervical cancer	0.0293	0.0577	CbGeAlD
Naproxen—AKR1C3—decidua—cervical cancer	0.0279	0.055	CbGeAlD
Naproxen—AKR1C3—endometrium—cervical cancer	0.0265	0.0522	CbGeAlD
Naproxen—AKR1C3—mammalian vulva—cervical cancer	0.0256	0.0505	CbGeAlD
Naproxen—UGT1A1—renal system—cervical cancer	0.0253	0.0498	CbGeAlD
Naproxen—AKR1C3—uterus—cervical cancer	0.0244	0.0481	CbGeAlD
Naproxen—UGT2B7—female reproductive system—cervical cancer	0.0238	0.0469	CbGeAlD
Naproxen—Heartburn—Topotecan—cervical cancer	0.0227	0.046	CcSEcCtD
Naproxen—Neuralgia—Topotecan—cervical cancer	0.0224	0.0456	CcSEcCtD
Naproxen—Lung disorder—Topotecan—cervical cancer	0.022	0.0447	CcSEcCtD
Naproxen—AKR1C3—female gonad—cervical cancer	0.02	0.0394	CbGeAlD
Naproxen—AKR1C3—vagina—cervical cancer	0.0198	0.0391	CbGeAlD
Naproxen—SLCO1A2—renal system—cervical cancer	0.0171	0.0337	CbGeAlD
Naproxen—Bone pain—Topotecan—cervical cancer	0.0163	0.033	CcSEcCtD
Naproxen—Colitis—Topotecan—cervical cancer	0.015	0.0304	CcSEcCtD
Naproxen—Sepsis—Topotecan—cervical cancer	0.0135	0.0275	CcSEcCtD
Naproxen—AKR1C3—lymph node—cervical cancer	0.0128	0.0253	CbGeAlD
Naproxen—CYP2C8—renal system—cervical cancer	0.012	0.0236	CbGeAlD
Naproxen—Dermatitis bullous—Topotecan—cervical cancer	0.0118	0.024	CcSEcCtD
Naproxen—Anaphylactoid reaction—Topotecan—cervical cancer	0.0117	0.0237	CcSEcCtD
Naproxen—CYP2C8—endometrium—cervical cancer	0.0116	0.0228	CbGeAlD
Naproxen—CYP1A2—renal system—cervical cancer	0.0112	0.0221	CbGeAlD
Naproxen—PTGS1—epithelium—cervical cancer	0.0105	0.0206	CbGeAlD
Naproxen—PTGS1—uterine cervix—cervical cancer	0.0104	0.0204	CbGeAlD
Naproxen—Cramp muscle—Topotecan—cervical cancer	0.0102	0.0207	CcSEcCtD
Naproxen—PTGS2—epithelium—cervical cancer	0.00999	0.0197	CbGeAlD
Naproxen—PTGS2—uterine cervix—cervical cancer	0.00991	0.0195	CbGeAlD
Naproxen—PTGS1—renal system—cervical cancer	0.0097	0.0191	CbGeAlD
Naproxen—CYP2C8—female reproductive system—cervical cancer	0.00958	0.0189	CbGeAlD
Naproxen—PTGS1—endometrium—cervical cancer	0.00937	0.0185	CbGeAlD
Naproxen—Pancytopenia—Topotecan—cervical cancer	0.00929	0.0189	CcSEcCtD
Naproxen—PTGS2—renal system—cervical cancer	0.00927	0.0183	CbGeAlD
Naproxen—PTGS1—mammalian vulva—cervical cancer	0.00907	0.0179	CbGeAlD
Naproxen—PTGS2—endometrium—cervical cancer	0.00896	0.0177	CbGeAlD
Naproxen—Pneumonia—Topotecan—cervical cancer	0.00878	0.0178	CcSEcCtD
Naproxen—CYP2C8—vagina—cervical cancer	0.00866	0.0171	CbGeAlD
Naproxen—PTGS1—uterus—cervical cancer	0.00864	0.017	CbGeAlD
Naproxen—Neuropathy peripheral—Topotecan—cervical cancer	0.00855	0.0174	CcSEcCtD
Naproxen—CYP2C9—female reproductive system—cervical cancer	0.00851	0.0168	CbGeAlD
Naproxen—Stomatitis—Topotecan—cervical cancer	0.0085	0.0173	CcSEcCtD
Naproxen—Sweating—Topotecan—cervical cancer	0.00836	0.017	CcSEcCtD
Naproxen—PTGS2—uterus—cervical cancer	0.00826	0.0163	CbGeAlD
Naproxen—Hepatobiliary disease—Topotecan—cervical cancer	0.00825	0.0167	CcSEcCtD
Naproxen—Epistaxis—Topotecan—cervical cancer	0.00823	0.0167	CcSEcCtD
Naproxen—ALB—lymph node—cervical cancer	0.00797	0.0157	CbGeAlD
Naproxen—Haemoglobin—Topotecan—cervical cancer	0.00787	0.016	CcSEcCtD
Naproxen—Rhinitis—Topotecan—cervical cancer	0.00785	0.0159	CcSEcCtD
Naproxen—Haemorrhage—Topotecan—cervical cancer	0.00783	0.0159	CcSEcCtD
Naproxen—Pharyngitis—Topotecan—cervical cancer	0.00777	0.0158	CcSEcCtD
Naproxen—PTGS1—female reproductive system—cervical cancer	0.00777	0.0153	CbGeAlD
Naproxen—PTGS2—female reproductive system—cervical cancer	0.00742	0.0146	CbGeAlD
Naproxen—Angiopathy—Topotecan—cervical cancer	0.00711	0.0144	CcSEcCtD
Naproxen—Immune system disorder—Topotecan—cervical cancer	0.00707	0.0144	CcSEcCtD
Naproxen—PTGS1—female gonad—cervical cancer	0.00707	0.0139	CbGeAlD
Naproxen—Mediastinal disorder—Topotecan—cervical cancer	0.00706	0.0143	CcSEcCtD
Naproxen—Chills—Topotecan—cervical cancer	0.00703	0.0143	CcSEcCtD
Naproxen—PTGS1—vagina—cervical cancer	0.00702	0.0138	CbGeAlD
Naproxen—Alopecia—Topotecan—cervical cancer	0.00692	0.014	CcSEcCtD
Naproxen—Malnutrition—Topotecan—cervical cancer	0.00682	0.0138	CcSEcCtD
Naproxen—PTGS2—female gonad—cervical cancer	0.00675	0.0133	CbGeAlD
Naproxen—PTGS2—vagina—cervical cancer	0.00671	0.0132	CbGeAlD
Naproxen—Muscle spasms—Topotecan—cervical cancer	0.00656	0.0133	CcSEcCtD
Naproxen—Ill-defined disorder—Topotecan—cervical cancer	0.00633	0.0128	CcSEcCtD
Naproxen—Anaemia—Topotecan—cervical cancer	0.0063	0.0128	CcSEcCtD
Naproxen—Angioedema—Topotecan—cervical cancer	0.00623	0.0126	CcSEcCtD
Naproxen—Malaise—Topotecan—cervical cancer	0.00615	0.0125	CcSEcCtD
Naproxen—Leukopenia—Topotecan—cervical cancer	0.0061	0.0124	CcSEcCtD
Naproxen—Cough—Topotecan—cervical cancer	0.00595	0.0121	CcSEcCtD
Naproxen—Arthralgia—Topotecan—cervical cancer	0.0058	0.0118	CcSEcCtD
Naproxen—Myalgia—Topotecan—cervical cancer	0.0058	0.0118	CcSEcCtD
Naproxen—Chest pain—Topotecan—cervical cancer	0.0058	0.0118	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00576	0.0117	CcSEcCtD
Naproxen—Discomfort—Topotecan—cervical cancer	0.00574	0.0116	CcSEcCtD
Naproxen—Anaphylactic shock—Topotecan—cervical cancer	0.00556	0.0113	CcSEcCtD
Naproxen—Infection—Topotecan—cervical cancer	0.00553	0.0112	CcSEcCtD
Naproxen—Nervous system disorder—Topotecan—cervical cancer	0.00546	0.0111	CcSEcCtD
Naproxen—Thrombocytopenia—Topotecan—cervical cancer	0.00545	0.0111	CcSEcCtD
Naproxen—Skin disorder—Topotecan—cervical cancer	0.00541	0.011	CcSEcCtD
Naproxen—Hyperhidrosis—Topotecan—cervical cancer	0.00538	0.0109	CcSEcCtD
Naproxen—Anorexia—Topotecan—cervical cancer	0.0053	0.0108	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00507	0.0103	CcSEcCtD
Naproxen—Paraesthesia—Topotecan—cervical cancer	0.005	0.0101	CcSEcCtD
Naproxen—Dyspnoea—Topotecan—cervical cancer	0.00496	0.0101	CcSEcCtD
Naproxen—Dyspepsia—Topotecan—cervical cancer	0.0049	0.00994	CcSEcCtD
Naproxen—Decreased appetite—Topotecan—cervical cancer	0.00484	0.00982	CcSEcCtD
Naproxen—Gastrointestinal disorder—Topotecan—cervical cancer	0.0048	0.00975	CcSEcCtD
Naproxen—Fatigue—Topotecan—cervical cancer	0.0048	0.00974	CcSEcCtD
Naproxen—Constipation—Topotecan—cervical cancer	0.00476	0.00966	CcSEcCtD
Naproxen—Pain—Topotecan—cervical cancer	0.00476	0.00966	CcSEcCtD
Naproxen—Feeling abnormal—Topotecan—cervical cancer	0.00459	0.00931	CcSEcCtD
Naproxen—Gastrointestinal pain—Topotecan—cervical cancer	0.00455	0.00924	CcSEcCtD
Naproxen—PTGS1—lymph node—cervical cancer	0.00454	0.00895	CbGeAlD
Naproxen—Urticaria—Topotecan—cervical cancer	0.00442	0.00897	CcSEcCtD
Naproxen—Body temperature increased—Topotecan—cervical cancer	0.0044	0.00893	CcSEcCtD
Naproxen—Abdominal pain—Topotecan—cervical cancer	0.0044	0.00893	CcSEcCtD
Naproxen—PTGS2—lymph node—cervical cancer	0.00434	0.00856	CbGeAlD
Naproxen—Hypersensitivity—Topotecan—cervical cancer	0.0041	0.00832	CcSEcCtD
Naproxen—Asthenia—Topotecan—cervical cancer	0.00399	0.0081	CcSEcCtD
Naproxen—Pruritus—Topotecan—cervical cancer	0.00394	0.00799	CcSEcCtD
Naproxen—Diarrhoea—Topotecan—cervical cancer	0.00381	0.00773	CcSEcCtD
Naproxen—Dizziness—Topotecan—cervical cancer	0.00368	0.00747	CcSEcCtD
Naproxen—Vomiting—Topotecan—cervical cancer	0.00354	0.00718	CcSEcCtD
Naproxen—Rash—Topotecan—cervical cancer	0.00351	0.00712	CcSEcCtD
Naproxen—Dermatitis—Topotecan—cervical cancer	0.00351	0.00711	CcSEcCtD
Naproxen—Headache—Topotecan—cervical cancer	0.00349	0.00708	CcSEcCtD
Naproxen—Nausea—Topotecan—cervical cancer	0.00331	0.00671	CcSEcCtD
